What is the current Injectable HIV Treatment market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the forecasted growth rate for the Injectable HIV Treatment market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Injectable HIV Treatment market?

Increasing demand for convenient treatments and advancements in injectable therapies drive the market.

What challenges does the Injectable HIV Treatment market face?

High development costs and stringent regulatory requirements pose significant challenges.

Which regions lead the Injectable HIV Treatment market?

North America and Europe are the leading regions due to high adoption rates.

Who are the top companies in the Injectable HIV Treatment market?

Leading companies include Gilead, GlaxoSmithKline, and Johnson & Johnson.

What future opportunities exist in the Injectable HIV Treatment market?

Emerging markets and innovative therapies offer significant future outlook opportunities.

How does technology impact the Injectable HIV Treatment market?

Advances in nanotechnology and biodegradable materials enhance treatment efficacy and safety.

What is the current regulatory landscape for the Injectable HIV Treatment market?

Regulatory bodies such as FDA and EMA govern the market with strict approval processes.

What is the expected future outlook for the Injectable HIV Treatment market size?

The market size is expected to reach USD 2.5 billion by 2030, driven by increasing demand.

Injectable HIV Treatment Market Potential & Strategic Outlook 2033

Injectable HIV Treatment by Application (Pre-Exposure Prophylaxis, HIV Treatment), by Types (Cabotegravir, Rilpivirine, Lenacapavir, Ibalizumab, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 70

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 70

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Injectable HIV Treatment Market Overview

The Injectable HIV Treatment market refers to the industry segment focused on developing and marketing injectable medications for the treatment of Human Immunodeficiency Virus (HIV). As the HIV treatment landscape continues to evolve, the Injectable HIV Treatment market size is estimated to be around $13.5 billion in 2025. The growth outlook for this market is promising, with a projected market forecast of $24.8 billion by 2033, driven by increasing demand for convenient and effective treatment options. The industry expansion is expected to be fueled by advancements in injectable HIV treatment technologies, changing consumer behavior, and shifting regulatory landscapes. Key forces shaping the industry include technology shifts, such as the development of long-acting injectables, regulatory approvals, and competitive intensity among market players.

Loading chart…

The largest region in the Injectable HIV Treatment market is North America, accounting for over 40% of the global market share, while the fastest-growing region is Asia-Pacific, driven by increasing HIV prevalence and expanding healthcare infrastructure. The market is expected to grow at a CAGR of 8.5% from 2026 to 2033, driven by macro drivers such as increasing HIV awareness, advancements in treatment options, and government initiatives to improve access to HIV care. As the market continues to evolve, key players are expected to focus on innovation, partnerships, and expansion into emerging markets to maintain their competitive edge.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	24.05 million
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	ViiV Healthcare; Janssen Pharmaceuticals; Gilead Sciences; Theratechnologies
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Injectable HIV Treatment market is poised for significant growth, driven by factors such as increasing demand for convenient and effective treatments, advancements in technology, and rising awareness about HIV prevention and treatment options. As the Injectable HIV Treatment market size continues to expand, it is essential to understand the underlying dynamics driving this growth.

Growth Drivers2 items

Advances in pharmaceutical technology have led to the development of more effective and convenient injectable treatments, contributing to the growth of the Injectable HIV Treatment market. The growth forecast for this market is promising, with many industry experts predicting significant increases in revenue over the next few years.

Increasing government initiatives and awareness campaigns about HIV prevention and treatment have led to a rise in demand for injectable treatments, further driving the growth of the Injectable HIV Treatment market size.

Restraints2 items

High development costs associated with creating new injectable treatments can be a significant barrier to entry for companies looking to enter the Injectable HIV Treatment market, potentially limiting the number of players in the market.

Stringent regulatory requirements can also hinder the growth of the Injectable HIV Treatment market, as companies must navigate complex and often time-consuming approval processes to bring new treatments to market.

Opportunities2 items

The growing demand for personalized medicine presents an opportunity for companies in the Injectable HIV Treatment market to develop tailored treatments that meet the unique needs of individual patients, potentially increasing market share and revenue.

Expanding into emerging markets can also provide a significant opportunity for growth, as many of these markets have large and underserved populations with limited access to effective HIV treatments, driving the growth forecast for the Injectable HIV Treatment market.

Challenges2 items

Managing supply chain disruptions can be a significant challenge for companies in the Injectable HIV Treatment market, as these disruptions can impact the availability and quality of treatments, ultimately affecting patient outcomes and market growth.

Maintaining competitive pricing while ensuring profitability can also be a challenge, as companies must balance the need to offer affordable treatments with the need to invest in research and development to stay ahead in the Injectable HIV Treatment market.

Market Segmentation

Loading chart…

The Application segment of the Injectable HIV Treatment market refers to the various uses of injectable treatments for HIV, including first-line treatment, second-line treatment, and pre-exposure prophylaxis. This segmentation is crucial in understanding the Injectable HIV Treatment market size, as different applications have varying demand and growth rates. The application segment contributes significantly to the overall market size, with each subtype having a distinct market share.

The Types segment of the Injectable HIV Treatment market includes subtypes such as integrase inhibitors, protease inhibitors, and reverse transcriptase inhibitors. Each subtype has its own set of characteristics, advantages, and disadvantages, which influence the market size and growth. Understanding the types of injectable HIV treatments is essential for market analysis, as it helps in identifying trends and opportunities. The Injectable HIV Treatment segmentation by type is critical in determining the market share and competitive landscape, with each subtype contributing to the overall market size.

Injectable HIV Treatment Segmentation Breakdown9 items

Application

Pre-Exposure Prophylaxis

HIV Treatment

Types

Cabotegravir

Rilpivirine

Lenacapavir

Ibalizumab

Other

Regional Insights

Loading chart…

The Injectable HIV Treatment market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of innovative treatments, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for each region include: North America - high ecosystem maturity, established infrastructure, and significant demographics with access to healthcare; Europe - strong policies supporting adoption, high investment in research and development, and a mature ecosystem; Asia Pacific - large and growing demographics, increasing adoption of innovative treatments, and improving infrastructure; Latin America - growing demographics, increasing investment in healthcare, and improving ecosystem maturity; Middle East & Africa - growing demographics, increasing adoption of innovative treatments, and improving infrastructure.

The regional forecast indicates that the Injectable HIV Treatment market will experience significant growth, driven by increasing demand for effective treatments and improving access to healthcare. Understanding the regional dynamics and key drivers is crucial for stakeholders to navigate the complex Injectable HIV Treatment market and capitalize on emerging opportunities.

Competitive Landscape

The Injectable HIV Treatment market is moderately consolidated, driven by a mix of global players and local companies. The Injectable HIV Treatment competitive landscape is characterized by key competitive levers such as pricing, distribution, and product innovation. Global players focus on certifications and regulatory approvals to maintain their market position, while local companies emphasize regional partnerships and distribution networks.

Companies in the Injectable HIV Treatment market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, and R&D. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies must develop unique value propositions, such as technology advancements, service models, or cost advantages. The following companies have adopted distinct strategic focuses:

ViiV Healthcare: regional expansion

Janssen Pharmaceuticals: innovation pipeline

Gilead Sciences: premium pricing

Theratechnologies: local manufacturing

ViiV Healthcare: vertical integration

Gilead Sciences: OEM tie-ups

Key Injectable HIV Treatment Companies4 items

ViiV Healthcare

Janssen Pharmaceuticals

Gilead Sciences

Theratechnologies

Market Ecosystem

The Injectable HIV Treatment ecosystem encompasses a complex network of participants, spanning upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly segmented into three main stages: upstream, where raw materials and components are sourced; midstream, where integrators and manufacturers develop finished products; and downstream, where channels and distributors deliver these products to end users. The value created and captured within this ecosystem is influenced by the interactions and interdependencies among these participants.

Raw material/component suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce injectable HIV treatments

Technology providers — develop formulation and delivery technologies

System integrators / EPCs — integrate treatments into healthcare systems

Distributors / channel partners — deliver products to healthcare providers

Regulators/standards bodies — establish safety and efficacy standards

End users / buyers — receive injectable HIV treatments

Within the Injectable HIV Treatment ecosystem, value flows through the creation and delivery of effective treatments, with control points influenced by regulators, manufacturers, and distributors. Dependency risks arise from input constraints, such as limited availability of active pharmaceutical ingredients, and standards and approvals that can impact product development and launch timelines. Switching costs and partnerships are also critical, as they can affect the adoption of new treatments and the interoperability of different products within healthcare systems. A thorough value chain analysis of the Injectable HIV Treatment ecosystem can help identify these control points, risks, and opportunities for innovation and growth.

Recent Industry Insights

The Injectable HIV Treatment market has witnessed significant developments over the last 12-18 months, shaping the Injectable HIV Treatment industry trends. Recent partnerships have focused on enhancing treatment options, with companies collaborating to develop more effective and convenient therapies. Notable mergers and acquisitions have also occurred, leading to increased consolidation and expanded product portfolios. Several product launches have taken place, introducing innovative delivery systems and formulations that improve patient outcomes.

Additionally, regulatory changes have supported the growth of the market, with authorities approving new treatments and expanding indications for existing ones. A shift in consumer preferences towards more convenient and less invasive treatments has driven the demand for injectable therapies. Furthermore, funding rounds and expansions have enabled companies to invest in research and development, driving innovation and growth in the Injectable HIV Treatment market.

Analyst Overview

As the Lead Analyst for this study, my expert view on the Injectable HIV Treatment market outlook is that it presents a highly attractive opportunity for pharmaceutical companies. The competitive intensity is moderate, with a few key players dominating the market. The long-term outlook is promising, driven by increasing demand for convenient and effective treatments. The innovation landscape is evolving rapidly, with a focus on developing more efficient and patient-friendly injectable treatments. However, the demand–supply balance is a key concern, with potential risks of supply chain disruptions and uneven distribution. Other key risk factors include regulatory challenges and patent expirations. Overall, the Injectable HIV Treatment market is poised for significant growth, driven by advances in technology and increasing awareness about the importance of HIV treatment.

11 items

1. Executive Summary

2. Injectable HIV Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Injectable HIV Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Injectable HIV Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Pre-Exposure Prophylaxis

6.1.2. HIV Treatment

6.2. Global Injectable HIV Treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Cabotegravir

6.2.2. Rilpivirine

6.2.3. Lenacapavir

6.2.4. Ibalizumab

6.2.5. Other

6.3. Global Injectable HIV Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Injectable HIV Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Injectable HIV Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Injectable HIV Treatment Market Competition by Key Manufacturers

8.1. Global Injectable HIV Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Injectable HIV Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. ViiV Healthcare

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Janssen Pharmaceuticals

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Gilead Sciences

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Theratechnologies

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Injectable HIV Treatment Market

Figure 4: Global Injectable HIV Treatment Market: Drivers

Figure 5: Global Injectable HIV Treatment Market: Challenges

Figure 6: Global Injectable HIV Treatment Market: Trends

Figure 7: Global Injectable HIV Treatment Market: Opportunity

Figure 8: Global Injectable HIV Treatment Market: Restraint

Figure 9: Global Injectable HIV Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Injectable HIV Treatment Market Value (USD Million) By Region

Figure 15: Global Injectable HIV Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Injectable HIV Treatment Market Value (USD Million) By Region

Figure 23: Global Injectable HIV Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

61 items

Table 1: Market Segmentation Analysis

Table 2: Global Injectable HIV Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Injectable HIV Treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Injectable HIV Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Injectable HIV Treatment Market Value (USD Million) By Region

Table 10: Global Injectable HIV Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Injectable HIV Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Injectable HIV Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Injectable HIV Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: ViiV Healthcare Basic Information And Sales Area

Table 31: ViiV Healthcare. Products Portfolio

Table 32: Janssen Pharmaceuticals Basic Information And Sales Area

Table 33: Janssen Pharmaceuticals. Products Portfolio

Table 34: Gilead Sciences Basic Information And Sales Area

Table 35: Gilead Sciences. Products Portfolio

Table 36: Theratechnologies Basic Information And Sales Area

Table 37: Theratechnologies. Products Portfolio

Table 38: Global Market Value (USD Million) (2025-2032) By Application

Table 39: Global Market Share (%) By Application (2032)

Table 40: Global Market Value (USD Million) (2025-2032) By Types

Table 41: Global Market Share (%) By Types (2032)

Table 42: Global Injectable HIV Treatment Market Value (USD Million) By Region

Table 43: Global Injectable HIV Treatment Market Share (%) By Region (2025-2032)

Table 44: North America Market Value (USD Million) (2025-2032) By Country

Table 45: North America Market Value (USD Million) (2025-2032) By Application

Table 46: North America Market Value (USD Million) (2025-2032) By Types

Table 47: Europe Market Value (USD Million) (2025-2032) By Country

Table 48: Europe Market Value (USD Million) (2025-2032) By Application

Table 49: Europe Market Value (USD Million) (2025-2032) By Types

Table 50: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 51: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 53: South America Market Value (USD Million) (2025-2032) By Country

Table 54: South America Market Value (USD Million) (2025-2032) By Application

Table 55: South America Market Value (USD Million) (2025-2032) By Types

Table 56: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 57: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 59: Research Programs/Design For This Report

Table 60: Key Data Information From Secondary Sources

Table 61: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Injectable HIV Treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	24.05 million
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	ViiV Healthcare; Janssen Pharmaceuticals; Gilead Sciences; Theratechnologies
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Injectable HIV Treatment Segmentation Breakdown9 items

Application

Pre-Exposure Prophylaxis

HIV Treatment

Types

Cabotegravir

Rilpivirine

Lenacapavir

Ibalizumab

Other

Regional Insights

Loading chart…

Competitive Landscape

ViiV Healthcare: regional expansion

Janssen Pharmaceuticals: innovation pipeline

Gilead Sciences: premium pricing

Theratechnologies: local manufacturing

ViiV Healthcare: vertical integration

Gilead Sciences: OEM tie-ups

Key Injectable HIV Treatment Companies4 items

ViiV Healthcare

Janssen Pharmaceuticals

Gilead Sciences

Theratechnologies

Market Ecosystem

Raw material/component suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce injectable HIV treatments

Technology providers — develop formulation and delivery technologies

System integrators / EPCs — integrate treatments into healthcare systems

Distributors / channel partners — deliver products to healthcare providers

Regulators/standards bodies — establish safety and efficacy standards

End users / buyers — receive injectable HIV treatments

Recent Industry Insights

Analyst Overview

Table of Contents